Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
|Articles|July 30, 2014
- NSCLC (Issue 3)
- Volume 3
- Issue 1
<em>RICTOR</em> Amplification in Lung Cancer
Author(s)Bilal Piperdi, MD
Bilal Piperdi, MD, discusses an analysis presented at the 2014 ASCO Annual Meeting that looked at RICTOR amplification to define a subset of patients with lung cancer.
Advertisement
Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, director, Lung Cancer Program, Montefiore Einstein Center for Cancer Care, discusses an analysis presented at the 2014 ASCO Annual Meeting that looked atRICTORamplification to define a subset of patients with lung cancer.
Read more about defining subsets and predicting outcomes in lung cancer > >
Articles in this issue
about 12 years ago
Update on Next-Generation Therapies for NSCLCabout 12 years ago
Adverse Events Associated With CO-1686about 12 years ago
Cabozantinib Plus Erlotinib for Advanced EGFR-Mutant NSCLCabout 12 years ago
Peer Discussion on Maintenance Therapy in NSCLCabout 12 years ago
Trials of Anti-PD-L1 in NSCLC Are Well Under WayAdvertisement
Related to this article
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Upfront Surgery Vs Total Neoadjuvant Therapy in Rectal Cancer
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5